Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide.


Updates from The Motley Fool

Latest updates on Gilead Sciences from Fool.com.  The Fool has written over 1200 articles on Gilead Sciences.
3 Value Stocks for Retirees

Shares of Gilead Sciences, General Motors, and American Outdoor Brands can all be bought for a so...



Stock Performance

View Interactive GILD Charts
Sponsored by

Key Data Points

Primary metrics and data points about Gilead Sciences.
Current Price: $72.30
Prev Close: $73.35
Open: $73.09
Bid: $72.51
Ask: $72.52
Day's Range: $72.36 - $73.41
52wk Range: $63.76 - $82.10
Volume: 2,167,442
Avg Vol 8,159,939
Market Cap: $94B
P/E (ttm): 7.96
EPS (ttm): $9.21
Div & Yield: $2.08 (2.8%)

Company Rating

What our community thinks about Gilead Sciences.
CAPS Rating 5 out of 5
 
3629 Outperform
85 Underperform
CAPS All Stars
 
756 Outperform
16 Underperform

How do you think Gilead Sciences will perform against the market?



You pick for Gilead Sciences is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

John Milligan, CEO

83% Approve

Based on 56 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Gilead Sciences.

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers